Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
- PMDA Announces 5 Themes for Trial of MID-NET Including Codeine, Denosumab
December 28, 2016
- HPV-Unvaccinated Teens Show Symptoms Similar to Post-Vaccine Reactions: Study
December 27, 2016
- MHLW Health Service Bureau’s FY2017 Budget at 369.2 Billion Yen
December 27, 2016
- MHLW Gives Orphan Status to Avelumab, 2 Other Compounds
December 26, 2016
- MHLW Allots 300 Million Yen for Health Minister-Pushed Startup Consultations
December 26, 2016
- MHLW Pharmaceutical Safety Bureau Earmarks 230 Mil. Yen for New Guidelines Initiative
December 26, 2016
- MHLW’s FY2017 Budget Up 1.2% at 30.7 Trillion Yen
December 26, 2016
- MHLW to Set Up MID-NET Usage Fees to Induce Drug Makers to Use It for PMS: Official
December 26, 2016
- AMED’s FY2017 Budget Earmarks 126.5 Billion Yen for Medical R&D
December 26, 2016
- Govt’s FY2017 Budget Includes 32 Trillion Yen for Social Security Spending
December 26, 2016
- PM Abe’s Panel to Keep Vigilant Eyes on Drug Prices, Reimbursement Fees
December 22, 2016
- Chuikyo to Discuss Annual Price Revision Plan in Concert with CEFP: Official
December 22, 2016
- Claims for Health Damage Compensation Continued to Increase in FY2015, Rising to 1,566: PMDA
December 22, 2016
- Blanket Driving Ban for 3 SNRIs Eased: MHLW
December 21, 2016
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
December 21, 2016
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
- Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…